Guanidino N-Substituted and N,N-Disubstituted Derivatives of the κ-Opioid Antagonist GNTI

Journal of Medicinal Chemistry

Volumn 46, Issue 25, 2003, Pages 5505-5511

  Black, Shannon L ^a   Chauvignac, Cedric ^a   Grundt, Peter ^a   Miller, Carl N ^b   Wood, Susan ^b   Traynor, John R ^b   Lewis, John W ^a   Husbands, Stephen M ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANIDINE DERIVATIVE; KAPPA OPIATE RECEPTOR ANTAGONIST;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CRICETINAE; GUANIDINES; HUMANS; MORPHINANS; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0345412537     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0309203     Document Type: Article

References (30)

1. Schenk, S.; Partridge, B.; Shippenberg, T. S. U69593, a kappa opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology 1999, 144, 339-346.
2. Mello, N. K.; Negus, S. S. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J. Pharmacol. Exp. Ther. 1998, 286, 812-824.
3. Archer, S.; Glick, S. D.; Bidlack, J. Cyclazocine revisited. Neurochem. Res. 1996, 21, 1369-1373.
4. Heidbreder, C. A.; Babovic-Vuksanovic, D.; Shoaib, M.; Shippenberg, T. S. Development of behavioural sensitisation to cocaine: Influence of kappa opioid receptor agonists. J. Pharmacol. Exp. Ther. 1995, 275, 150-163.
5. Shippenberg, T. S.; LeFavour, A.; Heidbreder, C. A. Kappa opioid receptor agonists prevent sensitisation to the conditioned rewarding effects of cocaine. J. Pharmacol. Exp. Ther. 1996, 276, 545-554.
6. Spealman, R. D.; Bergman, J. Opioid modulation of the discriminative stimulus effects of cocaine: Comparison of mu, kappa and delta agonists in squirrel monkeys discriminating low doses of cocaine. Behav. Pharmacol. 1994, 5, 21-31.
7. Vink, R.; Portoghese, P. S.; Faden, A. I. Kappa opioid antagonist improves cellular bioenergetics and recovery after traumatic brain injury. Am. J. Physiol. 1991, 261, R1527-R1532.
8. Newman, D. D.; Rajakumar, N.; Flumerfelt, B. A.; Stoessl, A. J. A kappa opioid antagonist blocks sensitisation in a rodent model of Parkinson's disease. Neuroreport 1997, 8, 669-672.
9. Mague, S. D.; Pliakas, A. M.; Todtenkopf, M. S.; Tomasiewicz, H. C.; Zhang, Y.; Stevens Jr, W. C.; Jones, R. M.; Portoghese, P. S.; Carlezon Jr., W. A. Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 2003, 305, 323-330.
10. Arjune, D.; Bodnar, R. J. Suppression of nocturnal, palatable and glucoprivic intake in rats by the kappa opioid antagonist, nor-binaltorphimine. Brain Res. 1990, 534, 313-316.
11. Katafuchi, T.; Hattori, Y.; Nagatomo, I.; Koizumi, K. Kappa opioid antagonist strongly attenuates drinking of genetically polydipsic mice. Brain Res. 1991, 546, 1-7.
12. Portoghese, P. S.; Lipkowski, A. W.; Takemori, A. E. Bimorphinans as highly selective, potent K-opioid receptor antagonists. J. Med. Chem. 1987, 30, 238-239.
13. Portoghese, P. S.; Lipkowski, A. W.; Takemori, A. E. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 1987, 40, 1287-1292.
14. Takemori, A. E.; Ho, B. Y.; Naeseth, J. S.; Portoghese, P. S. Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor-binding assays. J. Pharmacol. Exp. Ther. 1988, 246, 255-258.
15. Jones, R. M.; Hjorth, S. A.; Schwartz, T. W.; Portoghese, P. S. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. J. Med. Chem. 1998, 41, 4911-4914.
16. Jones, R. M.; Portoghese, P. S. 5′-Guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist. Eur. J. Pharmacol. 2000, 396, 49-52.
17. Negus, S. S.; Mello, N. K.; Linsenmayer, D. C.; Jones, R. M.; Portoghese, P. S. Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys Psychopharmacology 2002, 163, 412-419.
18. Grundt, P.; Jales, A. J.; Traynor, J. R.; Lewis, J. W.; Husbands, S. M. 14-Amino, 14-alkylamino- and 14-acylamino analogues of oxymorphindole. Differential effects on opioid receptor binding and functional profiles. J. Med. Chem. 2003, 46, 1563-1566.
19. Korlipara, V. L.; Takemori, A. E.; Portoghese, P. S. Electrophilic N-benzylnaltrindoles as δ-opioid receptor-selective antagonists. J. Med. Chem. 1995, 38, 1337-1343.
20. Korlipara, V. L.; Takemori, A. E.; Portoghese, P. S. N-Benzylnaltrindoles as long-acting δ-opioid receptor antagonists. J. Med. Chem. 1994, 37, 1882-1885.
21. Comer, S. D.; Burke, T. F.; Lewis, J. W.; Woods, J. H. Cloccinamox: A novel, systemically active, irreversible opioid antagonist. J. Pharmacol. Exp. Ther. 1992, 262, 1051-1056.
22. Burke, T. F.; Woods, J. H.; Lewis, J. W.; Medzihradsky, F. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J. Pharmacol. Exp. Ther. 1994, 271, 715-721.
23. Zernig, G.; Butelman, E.; Lewis, J. W.; Walker, E. A.; Woods, J. H. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J. Pharmacol. Exp. Ther. 1994, 269, 57-65.
24. Stevens, W. C.; Jones, R. M.; Subramanian, G.; Metzger, T. G.; Ferguson, D. M.; Portoghese, P. S. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J. Med. Chem. 2000, 43, 2759-2769.
25. Bender, D. M.; Williams, R. M. An efficient synthesis of (S)-m-tyrosine. J. Org. Chem. 1997, 62, 6690-6691.
26. Kashdan, D. S.; Schwartz, J. A.; Rapoport, H. Synthesis of 1,2,3,4-tetrahydroisoquinolines. J. Org. Chem. 1982, 47, 2638-2643.
27. 2 promoted guanylation reaction: The scope and limitations. Tetrahedron 1997, 53, 5291-5304.
28. Traynor, J. R.; Nahorski, S. R. Modulation by mu-opioid agonists of guanosine-5′-O-(3-[S-35]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 1995, 47, 848-854.
29. Toll, L.; Berzetei-Gurske, I. P.; Polgar, W. E.; Brandt, S. R.; Adapa, I. D.; Rodriguez, L.; Schwartz, R. W.; Haggart, D.; O'Brien, A.; White, A.; Kennedy, J. M.; Craymer, K.; Farrington, L.; Auh, J. S. Standard binding and functional assays related to (NIDA) Medications Development Division testing for potential cocaine and narcotic treatment programs. NIDA Res. Monogr. Ser. 1998, 178, 440-466.
30. Butelman, E. R.; Harris, T. J.; Kreek, M. J. Effects of E-2078, a stable dynorphin A(1-8) analogue on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacology. 1999, 147, 73-80.